​

Vivos Therapeutics Ownership | Who Owns Vivos Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Vivos Therapeutics Ownership Summary

Vivos Therapeutics is owned by 6.10% institutional investors, 8.00% insiders, and 85.90% retail investors. Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund, with 0.88% of its assets in Vivos Therapeutics shares.

VVOS Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockVivos Therapeutics6.10%8.00%85.90%
SectorHealthcare Stocks 279.19%10.58%-189.76%
IndustryMedical Device Stocks32.66%10.50%56.84%

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2025205.26%524,22012.11%69.68%12100.00%1-
Dec 31, 202419-13.64%467,59390.82%757.86%6-45.45%1-50.00%
Sep 30, 20242222.22%245,04831.11%311.05%1122.22%2100.00%
Jun 30, 20241820.00%186,89637.05%516.58%980.00%1-50.00%
Mar 31, 202415-6.25%136,374-46.93%53.01%5-2-80.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Institutional Extnd Mkt Idx Tr42.63K0.88%-
Fidelity Extended Market Index33.17K0.56%5.43K
Spartan Extended Market Index Pool F6.21K0.13%242.00
NT Ext Equity Mkt Idx Fd - NL6.80K0.12%6.27K
Fidelity Series Total Market Index6.63K0.11%376.00
Spartan Extended Market Index Pool E6.21K0.11%242.00
Fidelity Total Market Index5.83K0.10%-
NT Ext Equity Mkt Idx Fd - L5.63K0.10%-
Northern Trust Extended Eq Market Idx5.63K0.10%-
NT Ext Equity Mkt Idx Fd - DC - NL - T25.30K0.09%4.87K

Recent Insider Transactions

DateNameRoleActivityValue
Jun 20, 2023Huntsman Ronald Kirk Chief Executive OfficerBuy$7.42K
Jun 16, 2023Huntsman Ronald Kirk Chief Executive OfficerBuy$5.40K
Jun 16, 2023Huntsman Ronald Kirk Chief Executive OfficerBuy$2.65K
Jun 15, 2023Huntsman Ronald Kirk Chief Executive OfficerBuy$10.50
Jun 14, 2023Huntsman Ronald Kirk Chief Executive OfficerBuy$4.90K

Insider Transactions Trends

DateBuySell
2024 Q4--
2024 Q2--
2023 Q25-
2022 Q41-
2022 Q21-

VVOS Ownership FAQ

Who Owns Vivos Therapeutics?

Vivos Therapeutics shareholders are primarily institutional investors at 6.10%, followed by 8.00% insiders and 85.90% retail investors. The average institutional ownership in Vivos Therapeutics's industry, Medical Device Stocks, is 32.66%, which Vivos Therapeutics falls below.

Does Blackrock own Vivos Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Vivos Therapeutics.

Who is the top mutual fund holder of Vivos Therapeutics shares?

Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund holder of Vivos Therapeutics shares, with 0.88% of its total shares outstanding invested in 42.63K Vivos Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools